ABSTRACT BACKGROUND The optimal management of patients found to have multivessel disease while undergoing primary
The hypothesis was that early treatment of significant N-IRA lesions during the index admission would reduce global ischemic burden and protect against short-and medium-term recurrent ischemic events.
CvLPRIT and PRAMI ask a similar question but were initiated independently and with definitive differences in trial design.
METHODS
The study was initially conceived and funded as a pilot trial, with the first patient recruited in May 2011 at Glenfield Hospital, and then rolled out to 3 centers (Leeds General Infirmary, Southampton General Hospital, and Harefield Hospital) over the subsequent 6 months. With additional support from the funders, the study was extended to include 3 more sites (Kettering General Hospital, Royal Derby Hospital, and Royal Bournemouth Hospital). The sample size was determined after the publication of a study by Politi et al. (6) . The study rationale, design, and power calculation were published previously (7) Table 1 ). Potentially eligible patients were asked to provide Ethics Committee-approved verbal assent before coronary angiography, which was undertaken via the femoral or radial artery, according to operator preference. If patients fulfilled inclusion criteria after angiography, and before IRA P-PCI, randomization was undertaken via a 24-h automated, voice-activated central system. Patients were provided with full trial information within 24 h of PCI and were approached for written consent to continue in the study. Patients were treated after the procedure with contemporary optimal medical therapy. Cardiovascular magnetic resonance imaging was performed as a pre-specified substudy in 205 patients on 1.5-T scanners, as described previously (8) , at a median of 2.9 days (interquartile range [IQR]: 2.0 to 3.9 days) after P-PCI.
Blinded cardiac magnetic resonance analysis was undertaken at the University of Leicester core laboratory, and the results will be analyzed and reported separately.
CLINICAL OUTCOMES AND FOLLOW-UP. For safety reasons, all patients were scheduled for myocardial perfusion scintigraphy (MPS) at 6 AE 2 weeks after discharge to assess residual ischemia. All MPS examinations were analyzed at a core laboratory, with the investigator (A.D.K.) blinded to treatment status.
Scans were "nested" (used for study purposes only) but, for safety reasons, made available to physicians if the ischemic burden was >20%.
Telephone follow-up was conducted at 6 months for adverse clinical events. Patients were seen at 9 to 12 months to document major adverse cardiac events (MACE) comprising all-cause mortality, recurrent MI, heart failure (HF), and ischemic-driven revascularization by PCI/coronary artery bypass grafting (CABG).
Pre-specified secondary endpoints included cardiovascular death, individual components of the primary endpoint, and the safety endpoints of stroke, major bleeding, and contrast-induced nephropathy.
Clinicians blinded to the randomization group adjudicated all MACE and safety endpoints (definitions provided in Online Appendix 2). Ethics Committee permission was given to approach patients who were randomized in the study but who did not consent to continued participation, to verify vital status at 12 months. T r i a l g o v e r n a n c e . The sponsor was the University Gershlick et al.
Complete Versus Lesion-Only Primary PCI Trial Nineteen patients were lost to follow-up ( Figure 1 ).
These patients were tracked through a U.K. national database for their vital status, which confirmed that none had died.
The primary endpoint is presented as time to first event ( Table 3) . There was no increase in stroke, major bleeding (all non-CABG related), or contrast-induced nephropathy in the complete revascularization group ( Table 3) . Outcomes were similar between intention-to-treat groups, per protocol (Online Table 2 ), and in the as-treated population (Online Table 3 ). There was a significant reduction in the exploratory combined endpoint of all-cause mortality, recurrent MI, or HF in the complete revascularization group (p ¼ 0.025) (Online Table 4 ). There was a trend to reduced MACE in the population undergoing complete revascularization at the same sitting as IRA P-PCI compared with those having a staged procedure (Online Table 5 ). C o m p l e t e r e v a s c u l a r i z a t i o n g r o u p ( 7 e v e n t s ) .
One repeat PCI was symptom driven, 1 followed admission with troponin-negative ACS, 1 patient underwent attempted repeat PCI after failed N-IRA PCI at initial P-PCI, 3 underwent CABG after P-PCI to the IRA only at index admission (2 as outpatients, 1 as urgent inpatient CABG day 3 after P-PCI); and 1 patient had IRA-only revascularization and was readmitted electively at 6 weeks for further revascularization to the N-IRA.
I R A -o n l y r e v a s c u l a r i z a t i o n g r o u p ( 1 2 e v e n t s ) .
Ten patients underwent PCI for recurrent chest pain CvLPRIT data, in particular, showed early separation of the MACE curves, which in itself warrants discussion. In general, treatment of a significant stenosis by PCI, especially in stable patients, has been thought to lead to symptom improvement, rather than to influence prognosis. The recently published network meta-analysis by the European Myocardial Revascularization Collaboration suggests a potential mortality benefit as well (15) . This intriguing result calls our understanding of clinically silent "bystander" disease into question. There is emerging evidence of pan-coronary inflammation (16) and the presence of multiple unstable coronary plaques (17) , which may explain the higher incidence of recurrent ACS after STEMI than in patients with stable coronary disease (18) . Pacification of these bystander plaques may be proposed as a mechanism of benefit in complete revascularization. However, in our relatively small study, there were only 2 fewer spontaneous MIs (type 1) in the complete revascularization group than in the IRA-only group, which suggests that any effect of plaque pacification may be relatively small, but this should be the focus of mechanistic understanding in future larger trials. HR ¼ hazard ratio; IRA ¼ infarct-related artery; MACE ¼ major adverse cardiac event(s); MI ¼ myocardial infarction; N-IRA ¼ non-infarct-related artery. Table 3) . We acknowledge, however, that our definition of MI used was strict, because recurrent MI had to be driven by symptoms and was not recorded as being caused by increased periprocedural troponin increases alone (22) .
Because of the large enzyme release from the STEMI, small periprocedural infarcts related to revascularization of the non-IRA may have been missed. The frequency and size of these potentially important type 4b infarcts (23), as well as the effect on myocardial salvage and hibernating myocardium, will be addressed in the to-be-published cardiac magnetic resonance substudy. Further insights regarding the effect of complete revascularization on ischemia and how this relates to prognosis will be gathered from a nuclear imaging substudy that will be reported separately.
The subgroup analyses suggested benefit in all subgroups, particularly for women, those older than 65 years of age, and those with double-vessel disease, although the analyses were limited by the Gershlick et al.
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